<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746562</url>
  </required_header>
  <id_info>
    <org_study_id>1600-1116</org_study_id>
    <nct_id>NCT02746562</nct_id>
  </id_info>
  <brief_title>Study Comparing Outcomes Between Conventional IVF and a &quot;Freeze-all&quot;-Strategy in Assisted Reproductive Technology</brief_title>
  <official_title>A Multicentre Randomized Controlled Trial of a &quot;Freeze All and Transfer Later&quot; Versus a Conventional &quot;Fresh Embryo Transfer&quot; Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anja Bisgaard Pinborg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Skive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dexeus University Hospital Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare conventional fresh embryo transfer with a &quot;freeze all&#xD;
      and transfer later strategy&quot; in assisted reproductive technology in terms of ongoing&#xD;
      pregnancy rates, live birth rates as well as perinatal outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicentre randomized controlled double-blinded trial with the purpose to&#xD;
      investigate if pregnancy- and live birth rates can be improved by a &quot;freeze all and transfer&#xD;
      later&quot;-strategy with transfer of the best quality, frozen, thawed embryo in a subsequent&#xD;
      natural cycle compared with conventional fresh embryo transfer with transfer of the embryo in&#xD;
      the stimulated cycle.&#xD;
&#xD;
      In total 5 clinics in Denmark and Sweden will be participating in the recruitment of patients&#xD;
      for the study.&#xD;
&#xD;
      The patients will be screened and randomized computerized on cycle day 2 or 3 and allocated&#xD;
      to one of the two study arms:&#xD;
&#xD;
      I: hCG (human chorion gonadotrophin) arm with traditional hCG triggering and fresh blastocyst&#xD;
      transfer II: GnRH (gonadotropin-releasing hormone)- agonist triggering arm with blastocyst&#xD;
      cryopreservation and subsequent transfer in a subsequent natural cycle.&#xD;
&#xD;
      The randomization will be done after the decision of gonadotrophin (rFSH/hMG) starting dose,&#xD;
      and both doctor and patient will be blinded to the randomization until the day of hCG/agonist&#xD;
      trigger. Both groups will be stimulated in a short GnRH antagonist protocol. The ovarian&#xD;
      stimulation The gonadotrophin stimulation is performed according to the general standards in&#xD;
      each of the clinics and can be altered according to the ovarian response with a maximum of&#xD;
      300 IU.&#xD;
&#xD;
      Blood samples are collected at baseline before the first gonadotrophin injection and at day&#xD;
      of hCG injection and further blood samples in the luteal phase will be collected for a small&#xD;
      subgroup of patients. All blood samples will be kept at the Biobank for the study at Hvidovre&#xD;
      Hospital.&#xD;
&#xD;
      Women in both arms will furthermore be requested to fill out a physical discomfort and a&#xD;
      quality of life questionnaire at two different visits. Additionally the men will be asked to&#xD;
      fill out quality of life questionnaires.&#xD;
&#xD;
      Comprehensive sonography will be performed at the start of ovulation with details on each&#xD;
      ovary. Ultrasound examination is performed on cycle day 2-3, at stimulation day 6 and&#xD;
      thereafter every 2-3 days until ovulation is inducted.&#xD;
&#xD;
      On the day of oocyte retrieval the randomization is unblinded. The oocytes are fertilized by&#xD;
      either IVF or ICSI and cultured individually according to the normal procedures in the&#xD;
      clinics.&#xD;
&#xD;
      If the patient is allocated to the &quot;Fresh embryo transfer&quot;-group the best quality blastocyst&#xD;
      will be transferred on day five after oocyte pick-up, if a blastocyst is developed. Surplus&#xD;
      good quality blastocysts are vitrified on day five or six.&#xD;
&#xD;
      For patients in the &quot;Freeze all&quot; group all embryos of good quality are vitrified at the&#xD;
      blastocyst stage day 5 in the stimulated cycle according to the criteria for freezing&#xD;
      blastocysts in each clinic. The highest quality embryo is selected and marked and will be the&#xD;
      first one to be thawed after at least one mentrual cycle that is considered as a wash out&#xD;
      period. Embryo transfer is performed 6-7 days after hCG injection in the blastocyst transfer&#xD;
      cycle in this group.&#xD;
&#xD;
      A serum beta-hCG test is performed 11 days after blastocyst transfer, and clinical pregnancy&#xD;
      is confirmed by transvaginal ultrasound 3 to 4 weeks after a positive serum-hCG test.&#xD;
&#xD;
      A follow-up of all pregnancies will be performed within three months after delivery or&#xD;
      termination of pregnancy on predefined information sheets. All pregnancies resulting from&#xD;
      blastocysts retrieved and thawed according to this study protocol will be followed from study&#xD;
      inclusion and one year onwards.&#xD;
&#xD;
      All data will be collected in a single database and all participants will be anonymized by&#xD;
      way of an identificationcode. The biobank will be closed and all samples destroyed after 5&#xD;
      years of the conclusion of the study at the latest.&#xD;
&#xD;
      The study is a superiority study with 424 (212 in each arm) patients required to have an 80 %&#xD;
      chance of detecting, as significant at the 5 % level, a decrease in the primary outcome&#xD;
      measure from 30 % in the control group to 43 % in the experimental group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rates</measure>
    <time_frame>Two years</time_frame>
    <description>Outcome measured per transfer of the first blastocyst, per oocyte pick-up, per start of ovarian stimulation and per randomized patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth rates</measure>
    <time_frame>Two years</time_frame>
    <description>Outcome measured after the first blastocyst transfer calculated per randomized patient, per started ovarian stimulation, per oocyte pick-up and per transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative live birth rates</measure>
    <time_frame>Two years</time_frame>
    <description>Measured after one stimulated cycle with oocyte retrieval and after use of all frozen blastocysts or after at least 1 year of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles with no embryo transfer</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-pregnancy</measure>
    <time_frame>Two years</time_frame>
    <description>From start of ovarian stimulation to positive hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-delivery</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small-for-gestational age (SGA)</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large-for-gestational age (LGA)</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental rupture</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive hCG 11 days post embryo transfer</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriages, biochemical pregnancies, ectopic pregnancies</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for female and partner</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Freeze all</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresh embryo transfer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Freeze all</intervention_name>
    <description>Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle</description>
    <arm_group_label>Freeze all</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AMH (Anti-MÃ¼llerian hormone) &gt; 6.28 pmol/L (Roche Elecsys assay)&#xD;
&#xD;
          -  Female age 18 years to less than 40 years&#xD;
&#xD;
          -  1, 2 or 3 IVF/ICSI cycle with oocyte aspiration&#xD;
&#xD;
          -  Regular menstrual cycle between 24 and 35 days&#xD;
&#xD;
          -  BMI between 18 and 35&#xD;
&#xD;
          -  Two ovaries&#xD;
&#xD;
          -  Can and will sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who do not fulfil the inclusion criteria&#xD;
&#xD;
          -  Endometriosis stage III to IV&#xD;
&#xD;
          -  Ovarian cysts with diameter &gt; 30 mm at day of start of stimulation&#xD;
&#xD;
          -  Submucosal fibroids&#xD;
&#xD;
          -  Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular,&#xD;
             pulmonary, liver or kidney disease)&#xD;
&#xD;
          -  Dysregulation of thyroid disease&#xD;
&#xD;
          -  Not danish or English speaking women&#xD;
&#xD;
          -  Contraindications or allergies to use of Gonadotrophins or GnRH antagonists&#xD;
&#xD;
          -  TESA (testicular sperm aspiration)&#xD;
&#xD;
          -  OD (oocyte donation)&#xD;
&#xD;
          -  Previous inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Bisgaard Pinborg, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Fertility Clinic, Obstetrical and Gynecological department, Hvidovre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sacha Stormlund, MD</last_name>
    <email>sacha.stormlund.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Bisgaard Pinborg, MD, DMSc</last_name>
    <email>anja.bisgaard.pinborg@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Stormlund, MD</last_name>
      <email>sacha.stormlund.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Stormlund, MD</last_name>
      <email>sacha.stormlund.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Anja Pinborg, MD, DMSc</last_name>
      <email>anja.bisgaard.pinborg@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Anja Bisgaard Pinborg</investigator_full_name>
    <investigator_title>Professor, MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Assisted reproduction</keyword>
  <keyword>In vitro fertilisation</keyword>
  <keyword>Frozen embryo transfer (FET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

